Switching to camizestrant, a next-generation oral SERD, significantly prolongs progression-free survival and maintains ...

Dr. Massimo Cristofanilli discusses the early use of camizestrant with a CDK4/6 inhibitor to target ESR1 mutations, as it may improve outcomes in metastatic breast cancer.

Research on cancer metastasis uncovers genetic complexities, showing that copy-number alterations play a key role in tumor ...